This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1901)
- Annex to CHMP highlights(367)
- Annual Report(91)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(121)
- EPAR - All authorised presentations(1974)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2696)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(139)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(40)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Full risk management plan(1)
- EPAR - Overview(1970)
- EPAR - Paediatric investigation plan compliance statement(88)
- EPAR - Procedural steps taken and scientific information after authorisation(1873)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1970)
- EPAR - Public assessment report(1546)
- EPAR - Risk-management-plan summary(1134)
- EPAR - Scientific conclusion(1353)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(246)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(163)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(71)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Report(803)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(456)
- Medicines under additional monitoring(22)
- Minutes(1246)
- Newsletter(298)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4049)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2753)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5475)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5303)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Referrals document(2764)
- Regulatory and procedural guideline(722)
- Report(1616)
- Scientific guideline(2464)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1224)
- Summary of opinion - Initial authorisation(1672)
- Supply shortage(58)
- Template or form(478)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- Advanced therapies(1796)
- Antimicrobial resistance(270)
- Biologicals(147)
- Biosimilars(649)
- Brexit(121)
- Careers(5)
- Clinical trials(585)
- Compassionate use(16)
- Compliance and inspections(600)
- Corporate(111)
- COVID-19(898)
- Data on medicines(988)
- Early access(200)
- Fees(24)
- Generic and hybrid medicines(2176)
- Governance(675)
- Innovation(1164)
- Maximum residue limit(1001)
- Medication error(28)
- Medicines(46931)
- Medicines for use outside the EU(148)
- Medicine shortages(296)
- Mpox(39)
- Paediatrics(12234)
- Parallel distribution(15)
- Pharmacovigilance(9536)
- Procurement(132)
- Product information(6320)
- Quality of medicines(222)
- Rare diseases(8240)
- Referrals(3374)
- Regulatory and procedural guidance(3518)
- Research and development(494)
- Scientific advice(289)
- Scientific guidelines(1739)
- SME(259)
- Vaccines(1500)
- Veterinary limited markets(64)
Search results (84227)
Orkambi : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (212.83 KB - PDF)
Orkambi : EPAR - Product Information
English (EN) (956.09 KB - PDF)
български (BG) (1.08 MB - PDF)
español (ES) (991.02 KB - PDF)
čeština (CS) (1.12 MB - PDF)
dansk (DA) (988.45 KB - PDF)
Deutsch (DE) (1.02 MB - PDF)
eesti keel (ET) (1.09 MB - PDF)
ελληνικά (EL) (1.31 MB - PDF)
français (FR) (1.19 MB - PDF)
hrvatski (HR) (1.06 MB - PDF)
íslenska (IS) (947.07 KB - PDF)
italiano (IT) (1 MB - PDF)
latviešu valoda (LV) (1.04 MB - PDF)
lietuvių kalba (LT) (1018.83 KB - PDF)
magyar (HU) (1.14 MB - PDF)
Malti (MT) (1.1 MB - PDF)
Nederlands (NL) (924.62 KB - PDF)
norsk (NO) (911.49 KB - PDF)
polski (PL) (1.18 MB - PDF)
português (PT) (926.31 KB - PDF)
română (RO) (1.12 MB - PDF)
slovenčina (SK) (1.1 MB - PDF)
slovenščina (SL) (1.04 MB - PDF)
Suomi (FI) (971.41 KB - PDF)
svenska (SV) (946.78 KB - PDF)
Timetable: Post-authorisation safety study (PASS) protocols and final results
Timetable: Post-authorisation safety study (PASS) protocols and final results
English (EN) (100.07 KB - XLSX)
Luxturna-H-C-PSUSA-00010742-202307 : Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
English (EN) (130.4 KB - PDF)
Isentress : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (266.01 KB - PDF)
Isentress : EPAR - Product Information
English (EN) (1.7 MB - PDF)
български (BG) (1.61 MB - PDF)
español (ES) (1.91 MB - PDF)
čeština (CS) (1.6 MB - PDF)
dansk (DA) (1.76 MB - PDF)
Deutsch (DE) (1.93 MB - PDF)
eesti keel (ET) (1.84 MB - PDF)
ελληνικά (EL) (1.82 MB - PDF)
français (FR) (2.04 MB - PDF)
hrvatski (HR) (1.75 MB - PDF)
íslenska (IS) (1.71 MB - PDF)
italiano (IT) (1.86 MB - PDF)
latviešu valoda (LV) (1.64 MB - PDF)
lietuvių kalba (LT) (1.73 MB - PDF)
magyar (HU) (2.05 MB - PDF)
Malti (MT) (1.69 MB - PDF)
Nederlands (NL) (1.93 MB - PDF)
norsk (NO) (1.71 MB - PDF)
polski (PL) (2.08 MB - PDF)
português (PT) (1.86 MB - PDF)
română (RO) (1.89 MB - PDF)
slovenčina (SK) (1.82 MB - PDF)
slovenščina (SL) (1.79 MB - PDF)
Suomi (FI) (1.9 MB - PDF)
svenska (SV) (1.76 MB - PDF)
Spinraza : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (142.21 KB - PDF)
Spinraza : EPAR - Product Information
English (EN) (416.6 KB - PDF)
български (BG) (398.58 KB - PDF)
español (ES) (337.91 KB - PDF)
čeština (CS) (382.11 KB - PDF)
dansk (DA) (378.03 KB - PDF)
Deutsch (DE) (358.81 KB - PDF)
eesti keel (ET) (346 KB - PDF)
ελληνικά (EL) (402.72 KB - PDF)
français (FR) (456.7 KB - PDF)
hrvatski (HR) (415.47 KB - PDF)
íslenska (IS) (410.53 KB - PDF)
italiano (IT) (404.2 KB - PDF)
latviešu valoda (LV) (450.23 KB - PDF)
lietuvių kalba (LT) (455.92 KB - PDF)
magyar (HU) (456.32 KB - PDF)
Malti (MT) (442.33 KB - PDF)
Nederlands (NL) (442.47 KB - PDF)
norsk (NO) (395.2 KB - PDF)
polski (PL) (456.67 KB - PDF)
português (PT) (414.31 KB - PDF)
română (RO) (449.42 KB - PDF)
slovenčina (SK) (448.21 KB - PDF)
slovenščina (SL) (452.47 KB - PDF)
Suomi (FI) (409.75 KB - PDF)
svenska (SV) (409.94 KB - PDF)